These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19157562)

  • 1. Economic implications of current age-related macular degeneration treatments.
    Smiddy WE
    Ophthalmology; 2009 Mar; 116(3):481-7. PubMed ID: 19157562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications of cost analysis of diabetic macular edema treatments.
    Smiddy WE
    Ophthalmology; 2012 Dec; 119(12):2558-62. PubMed ID: 23062655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative cost of a line of vision in age-related macular degeneration.
    Smiddy WE
    Ophthalmology; 2007 May; 114(5):847-54. PubMed ID: 17306878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW; Cassard SD; Bass EB; Schein OD; Bressler NM
    Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of treatment of age-related macular degeneration: a review.
    Kymes Steven M
    Minerva Med; 2009 Feb; 100(1):69-78. PubMed ID: 19277005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of treatment for age-related macular degeneration.
    Gerson JD
    Optometry; 2009 Jul; 80(7):339. PubMed ID: 19753688
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M; Sharma S
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
    Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
    Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.
    Raftery J; Clegg A; Jones J; Tan SC; Lotery A
    Br J Ophthalmol; 2007 Sep; 91(9):1244-6. PubMed ID: 17431015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B; Adewoyin T; Patel SK; Sivaprasad S
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost of vision for vitreoretinal interventions.
    Smiddy WE
    Curr Opin Ophthalmol; 2008 May; 19(3):195-201. PubMed ID: 18408493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
    Fong DS; Custis P; Howes J; Hsu JW
    Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.